Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 22.4% – Still a Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares rose 22.4% during mid-day trading on Friday . The company traded as high as $0.41 and last traded at $0.40. Approximately 60,477,578 shares traded hands during trading, a decline of 24% from the average daily volume of 79,476,109 shares. The stock had previously closed at $0.33.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on Tonix Pharmaceuticals in a research report on Friday, January 17th. They set a “hold” rating for the company.

Tonix Pharmaceuticals Stock Up 21.8 %

The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The stock has a market capitalization of $74.57 million, a P/E ratio of -0.01 and a beta of 2.02. The firm has a 50 day moving average of $0.27 and a 200-day moving average of $0.29.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The firm had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. On average, equities research analysts expect that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. PFG Investments LLC purchased a new position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned about 0.12% of Tonix Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.